News and Events

Enzymlogic will be presenting its KINETICfinder® and COVALfinder® platforms on February 23rd at this 2-day event in Boston. The 2nd Next Generation Kinase Inhibitors Summit is the only industry-focused conference devoted to using novel kinase biology in drug development and innovating current programs to produce the next generation of kinase inhibitor drugs that can demonstrate…

Enzymlogic will be presenting its optimized kinetic profiling assays to identify reversible (KINETICfinder®) and irreversible compounds (COVALfinder®) at this 2-day event in Cambridge. The meeting will focus on the use of binding kinetics and mechanistic PK/PD modeling in informing early drug discovery decisions. Further, the deliberations will strive to delve deeper into the importance of…

Enzymlogic will participate in Drug Discovery 2022: Driving the next life science revolution ELRIG’s annual Drug Discovery meeting. The meeting will be held from 4–5th October at the ExCel in London and aims to present cutting-edge advancements in screening, automation and high content imaging, and innovations in disease models, advances in cell and gene therapies,…

As the kickoff to the DYRK1A, related kinases & human disease conference in Saint-Malo, France on November 22nd approaches, the Enzymlogic team is becoming increasingly excited. We are proud to have been selected to give a Podium Presentation highlighting the company’s KINETICfinder® and COVALfinder® technologies. During the podium presentation, entitled “Hunting for effective drugs with…

Enzymlogic will be presenting its KINETICfinder® and COVALfinder® platforms at this 2-day event in Boston alongside our academic collaborator Professor Peter Tonge (Stony Brook University), a world expert in kinetics. The presentation will be featured on November 18th as part of the Hit Finding Technologies and Advancements session. The Discovery US Congress 2022 will highlight…